Nothing Special   »   [go: up one dir, main page]

IL136905A0 - Recombinant rhabdovirus containing a heterologous fusion protein - Google Patents

Recombinant rhabdovirus containing a heterologous fusion protein

Info

Publication number
IL136905A0
IL136905A0 IL13690598A IL13690598A IL136905A0 IL 136905 A0 IL136905 A0 IL 136905A0 IL 13690598 A IL13690598 A IL 13690598A IL 13690598 A IL13690598 A IL 13690598A IL 136905 A0 IL136905 A0 IL 136905A0
Authority
IL
Israel
Prior art keywords
fusion protein
heterologous fusion
recombinant rhabdovirus
rhabdovirus containing
recombinant
Prior art date
Application number
IL13690598A
Other languages
English (en)
Original Assignee
Univ Tennessee Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Corp filed Critical Univ Tennessee Res Corp
Publication of IL136905A0 publication Critical patent/IL136905A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL13690598A 1997-12-22 1998-12-22 Recombinant rhabdovirus containing a heterologous fusion protein IL136905A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6847297P 1997-12-22 1997-12-22
PCT/US1998/026084 WO1999032648A1 (en) 1997-12-22 1998-12-22 Recombinant rhabdovirus containing a heterologous fusion protein

Publications (1)

Publication Number Publication Date
IL136905A0 true IL136905A0 (en) 2001-06-14

Family

ID=22082797

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13690598A IL136905A0 (en) 1997-12-22 1998-12-22 Recombinant rhabdovirus containing a heterologous fusion protein
IL136905A IL136905A (en) 1997-12-22 2000-06-20 Recombinant rehab virus containing heterologous fusion protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL136905A IL136905A (en) 1997-12-22 2000-06-20 Recombinant rehab virus containing heterologous fusion protein

Country Status (14)

Country Link
US (2) US6497873B1 (ja)
EP (1) EP1040198B1 (ja)
JP (1) JP4544497B2 (ja)
AP (1) AP1968A (ja)
AT (1) ATE451466T1 (ja)
AU (2) AU752004B2 (ja)
BR (1) BR9814370A (ja)
CA (1) CA2316033A1 (ja)
DE (1) DE69841372D1 (ja)
IL (2) IL136905A0 (ja)
MX (1) MXPA00006184A (ja)
NZ (1) NZ505312A (ja)
OA (1) OA11432A (ja)
WO (1) WO1999032648A1 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5060694B2 (ja) * 1999-09-17 2012-10-31 ウェルスタット バイオロジクス コーポレイション 腫瘍崩壊性ウイルス
AU2001281151A1 (en) * 2000-08-24 2002-03-04 Thomas Jefferson University Rhabdovirus-based vectors to express high levels of functional human antibodies
CA2440433A1 (en) * 2001-03-09 2002-09-19 The Regents Of The University Of California Cell culture system for synthesis of infectious hepatitis c virus
CA2452517A1 (en) * 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
US7820435B2 (en) * 2002-02-06 2010-10-26 Expression Technologies Inc. De novo synthesized plasmid, methods of making and use thereof
NZ542902A (en) 2003-03-27 2007-06-29 Ottawa Health Research Inst Mutant vesicular stomatitis viruses and use thereof
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
CA2526146A1 (en) * 2003-06-05 2005-02-24 Wyeth Holdings Corporation Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens
KR100999316B1 (ko) 2003-06-09 2010-12-10 와이어쓰 엘엘씨 ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의회수를 위한 개선된 방법
CN105769931B (zh) * 2006-09-15 2021-04-27 渥太华医院研究机构 溶瘤弹状病毒
WO2009014878A2 (en) * 2007-07-06 2009-01-29 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
US8703469B2 (en) 2007-07-06 2014-04-22 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
US20100215691A1 (en) 2009-02-20 2010-08-26 Parks Christopher L Recombinant viral vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
US9555067B2 (en) 2012-04-18 2017-01-31 Mayo Foundation For Medical Education And Research Replication-competent vesicular stomatitis viruses
FR2996856B1 (fr) * 2012-10-15 2015-06-05 Agronomique Inst Nat Rech Novirhabdovirus recombinant utilisable comme vecteur d'antigenes
KR20200003160A (ko) * 2017-05-03 2020-01-08 바이오마린 파머수티컬 인크. 조혈모세포의 형질도입을 위한 개선된 렌티바이러스
WO2018209052A1 (en) 2017-05-10 2018-11-15 Wellstat Immuno Therapeutics, Llc Enveloped virus resistant to complement inactivation for the treatment of cancer
JP2023513135A (ja) * 2020-02-06 2023-03-30 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 抗ラブドウイルス抗体を検出するのに有用なポリペプチド
WO2023051607A1 (zh) * 2021-09-29 2023-04-06 上海行深生物科技有限公司 病毒培养方法

Also Published As

Publication number Publication date
AP2000001852A0 (en) 2000-06-30
AU1905699A (en) 1999-07-12
AU2002300207B2 (en) 2006-07-13
WO1999032648A1 (en) 1999-07-01
IL136905A (en) 2007-10-31
NZ505312A (en) 2003-01-31
JP4544497B2 (ja) 2010-09-15
BR9814370A (pt) 2000-10-10
MXPA00006184A (es) 2003-02-11
ATE451466T1 (de) 2009-12-15
US20030138457A1 (en) 2003-07-24
OA11432A (en) 2004-04-26
EP1040198B1 (en) 2009-12-09
JP2001526901A (ja) 2001-12-25
EP1040198A1 (en) 2000-10-04
US6497873B1 (en) 2002-12-24
CA2316033A1 (en) 1999-07-01
AP1968A (en) 2009-04-30
DE69841372D1 (de) 2010-01-21
AU752004B2 (en) 2002-09-05

Similar Documents

Publication Publication Date Title
AP2000001852A0 (en) Recombinant rhabdovirus containing a heterologous fusion protein
AU2002300207A1 (en) Recombinant Rhabdovirus containing a heterologous Fusion Protein
GB9718609D0 (en) Fusion protein
AU7274898A (en) Recombinant antibody-enzyme fusion proteins
NZ330183A (en) Preparation of recombinant factor viii in a protein free medium
HUP0200414A2 (en) Interferon-betha fusion proteins and uses
AU5065198A (en) Fusion proteins having increased half-lives
HUP0302529A3 (en) Glp-1 fusion proteins
GB9112553D0 (en) Fusion proteins
EP1088888A4 (en) MERGED PROTEIN
AU8182298A (en) Recombinant erythropoietin / immunoglobulin fusion proteins
EP0973893A4 (en) POLYPEPTIDE LINKED TO AN INTRACELLULAR AMYLOID-BETA PEPTIDE (ERAB)
ZA976666B (en) Fusion polypeptides
IL122898A0 (en) Allergan -XCD32 fusion proteins
AU9798398A (en) Gfp-annexin fusion proteins
HUP0001477A3 (en) Calcitonin receptor-binding peptides
EP0700999A3 (en) Expression system using autolysed fusion proteins and a novel polypeptide
IL135942A0 (en) Assay employing cadc fusion proteins
HUP0004509A3 (en) Proteinase inhibitor fusion proteins
EP0855029A4 (en) HIGH YIELD ASSAY USING FUSION PROTEINS
HK1018479A1 (en) Dna encoding a plasminogen activating protein
IL91462A0 (en) Recombinant fusion proteins and dna encoding for such a protein
AU4661697A (en) Pfs28 fusion proteins
GB9713150D0 (en) Fusion proteins
GB9603486D0 (en) A high throughputassay using fusion proteins

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed